Ligand Pharmaceuticals (LGND) Other Accumulated Expenses (2010 - 2026)

Ligand Pharmaceuticals has disclosed Other Accumulated Expenses across 9 years of filings, most recently posting $300000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $300000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $300000.0 (changed N/A YoY), and the FY2025 annual result was $135000.0, down 89.63% from the prior year.
• Other Accumulated Expenses came in at $300000.0 for Q1 2026 at Ligand Pharmaceuticals, up from $135000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q4 2024 to a low of $135000.0 in Q3 2025.
• The 5-year median for Other Accumulated Expenses is $448000.0 (2023), against an average of $527571.4.
• Peak annual rise in Other Accumulated Expenses reached 89.63% in 2025, while the deepest fall reached 89.63% in 2025.
• Ligand Pharmaceuticals' Other Accumulated Expenses stood at $457000.0 in 2022, then jumped by 100.44% to $916000.0 in 2023, then jumped by 42.14% to $1.3 million in 2024, then sank by 89.63% to $135000.0 in 2025, then jumped by 122.22% to $300000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $300000.0 (Q1 2026), $135000.0 (Q4 2025), and $135000.0 (Q3 2025), per Business Quant data.